Cancer Research Infection and Cancer: Biology, Therapeutics, and Prevention  Susan G. Komen for the Cure-AACR Outstanding Investigator Award for Breast Cancer Research
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Cell Growth & Differentiation

[Cancer Research 15, 755-759, December 1, 1955]
© 1955 American Association for Cancer Research

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Sassenrath, E. N.
Right arrow Articles by Greenberg, D. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Sassenrath, E. N.
Right arrow Articles by Greenberg, D. M.

Evaluation of the Carcinostatic Activity of 1,2-Bis(ß-chloroethylthio)ethane*

Ethelda N. Sassenrath, Donald C. Morrison, Ann M. Larson and David M. Greenberg

( Department of Physiological Chemistry, University of California School of Medicine, Berkeley, Calif.)

1. 1,2-bis(ß-chloroethylthio)ethane (SM1) has been characterized relative to methylbis(ß-chloroethyl)amine (HN2) by studies of its toxicity and carcinostatic activity in mice and rats.
2. On a molar basis, SM1 was one-eighth as toxic as HN2. Toxic effects of both mustards on lymphatic tissues and intestine were comparable.
3. SM1 showed carcinostatic activity comparable to that of HN2 against the ascitic tumors and leukemias tested but a decreased activity against established solid tumors.
4. Pretreatment of animals with SM1 or HN2 before tumor transplanting revealed that the carcinostatic activity within the organism was more prolonged, while gross symptoms of toxicity were less severe with SM1.

* Aided by research grants from the American Cancer Society (Institutional Grant No. 43F), the National Cancer Institute (No. C-2074), U.S. Public Health Service, and the Damon Runyon Memorial Foundation.

Received 7/28/55.





HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Cell Growth & Differentiation
Copyright © 1955 by the American Association for Cancer Research.